Monoclonal antibodies associated IgA nephropathy or other nephropathies
4 affiliations
- 1Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences , ,
- 2Department of Inorganic Chemistry, Medical University of Gdansk , ,
- 3Carol & Richard Yu Peritoneal Dialysis Research Centre, Prince of Wales Hospital, Department of Medicine & Therapeutics, The Chinese University of Hong Kong , ,
- 4Department of General and Transplant Surgery, Poznan University of Medical Sciences , ,
Abstract
The use of monoclonal antibodies (mAbs) has revolutionized the treatment of autoimmune, inflammatory, and neoplastic diseases. However, accumulating evidence indicates that biologic therapies may be associated with renal adverse events, including various types of glomerulonephritis. The aim of this review was to summarize all reports available in the scientific literature regarding the occurrence of IgA nephropathy after monoclonal antibody treatment. Additionally, the risk of other glomerulonephritis after biologic therapy was discussed. IgA nephropathy (IgAN) is the most commonly reported glomerular lesion associated with monoclonal antibody therapy, particularly with TNF-α inhibitors such as infliximab, adalimumab, golimumab, and etanercept, as well as with immune checkpoint inhibitors targeting the PD-1 (pembrolizumab, nivolumab) and interleukin (ustekinumab) pathways. Proposed mechanisms include immune dysregulation with a shift toward Th2 and Th17-dependent responses, increased production of galactose-deficient IgA1, complement activation, formation of circulating immune complexes, and loss of immune tolerance. In some cases, drug discontinuation and glucocorticoid therapy have resulted in partial or complete disease remission, although progression to end-stage renal disease has also been reported. Due to the potential severity of these complications, initial and periodic monitoring of renal function and urinalysis are recommended in patients receiving monoclonal antibody therapy. Early recognition of renal involvement and prompt treatment modification can improve prognosis.
Related
- Novel monoclonal antibodies for an activated protein C cleavage neoepitope of coagulation factor Va
- Editorial: Monoclonal antibodies in treating multiple sclerosis (MS), and related diseases
- Targeting Integrins in Triple Negative Breast Cancer: Therapeutic Potential of Monoclonal Antibodies, PARP Inhibitors, Synthetic Peptides, and Aptamers
- 83 Translational PBPK modeling of PET imaging reveals enhanced predicted tumor exposure of antiCTLA4 singledomain antibody fragments vs. monoclonal antibodies
- Anti-Nectin4 monoclonal antibodies attenuate airway inflammation and epithelial barrier dysfunction in asthma
BibTeX
@article{miedziaszczyk2026monoclonal,
title = {{Monoclonal antibodies associated IgA nephropathy or other nephropathies}},
author = {Miłosz Miedziaszczyk and Gracjan Kosiorowski and Janusz Kubasik and Tomasz Grabowski and Edyta Szałek and Cheuk Chun Szeto and Ilona Idasiak-Piechocka},
journal = {Frontiers in pharmacology},
year = {2026},
month = sep,
doi = {10.3389/fphar.2026.1891000},
url = {https://europepmc.org/article/PMC/PMC13662283},
note = {CC BY},
}
RIS
TY - JOUR
TI - Monoclonal antibodies associated IgA nephropathy or other nephropathies
AU - Miłosz Miedziaszczyk
AU - Gracjan Kosiorowski
AU - Janusz Kubasik
AU - Tomasz Grabowski
AU - Edyta Szałek
AU - Cheuk Chun Szeto
AU - Ilona Idasiak-Piechocka
PY - 2026
DA - 2026/09/30
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1891000
UR - https://europepmc.org/article/PMC/PMC13662283
AB - The use of monoclonal antibodies (mAbs) has revolutionized the treatment of autoimmune, inflammatory, and neoplastic diseases. However, accumulating evidence indicates that biologic therapies may be associated with renal adverse events, including various types of glomerulonephritis. The aim of this review was to summarize all reports available in the scientific literature regarding the occurrence of IgA nephropathy after monoclonal antibody treatment. Additionally, the risk of other glomerulonephritis after biologic therapy was discussed. IgA nephropathy (IgAN) is the most commonly reported glomerular lesion associated with monoclonal antibody therapy, particularly with TNF-α inhibitors such as infliximab, adalimumab, golimumab, and etanercept, as well as with immune checkpoint inhibitors targeting the PD-1 (pembrolizumab, nivolumab) and interleukin (ustekinumab) pathways. Proposed mechanisms include immune dysregulation with a shift toward Th2 and Th17-dependent responses, increased production of galactose-deficient IgA1, complement activation, formation of circulating immune complexes, and loss of immune tolerance. In some cases, drug discontinuation and glucocorticoid therapy have resulted in partial or complete disease remission, although progression to end-stage renal disease has also been reported. Due to the potential severity of these complications, initial and periodic monitoring of renal function and urinalysis are recommended in patients receiving monoclonal antibody therapy. Early recognition of renal involvement and prompt treatment modification can improve prognosis.
SN - 1663-9812
ER -